Cited by 106Retinal Development and DisordersRetinal Diseases and TreatmentsAdvanced Drug Delivery Systems

Subretinal injection techniques for retinal disease: A review

Open access
Irigoyen, Cristina, Amenabar Alonso, Asier, Sanchez-Molina, Jorge, Rodríguez-Hidalgo, María, Lara-López, Araceli, Ruiz-Ederra, Javier·2022·Journal of Clinical Medicine

Abstract

Inherited retinal dystrophies (IRDs) affect an estimated 1 in every 2000 people, this corresponding to nearly 2 million cases worldwide. Currently, 270 genes have been associated with IRDs, most of them altering the function of photoreceptors and retinal pigment epithelium. Gene therapy has been proposed as a potential tool for improving visual function in these patients. Clinical trials in animal models and humans have been successful in various types of IRDs. Recently, voretigene neparvovec (Luxturna®) has been approved by the US Food and Drug Administration for the treatment of biallelic mutations in the RPE65 gene. The current state of the art in gene therapy involves the delivery of various types of viral vectors into the subretinal space to effectively transduce diseased photoreceptors and retinal pigment epithelium. For this, subretinal injection is becoming increasingly popular among researchers and clinicians. To date, several approaches for subretinal injection have been described in the scientific literature, all of them effective in accessing the subretinal space. The growth and development of gene therapy give rise to the need for a standardized procedure for subretinal injection that ensures the efficacy and safety of this new approach to drug delivery. The goal of this review is to offer an insight into the current subretinal injection techniques and understand the key factors in the success of this procedure.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm11164717

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Irigoyen, C., Amenabar Alonso, A., Sanchez-Molina, J., Rodríguez-Hidalgo, M., Lara-López, A., & Ruiz-Ederra, J.
Affiliations
  • University of the Basque Country (ES)
  • Department of Ophthalmology, Donostia University Hospital (HUD), 20014 Donostia San-Sebastián, Spain
  • Biogipuzkoa Health Research Institute (ES)
  • Miramoon Pharma S.L., Avenida de Tolosa, 72, 20018 San Sebastián, Spain
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2022-08-12
Volume
11
Issue
16
Pages
4717
ISSN
2077-0383 (ISSN-L)
OpenAlex
W4291465575
Cited by
106
References
88
Citations by year
2026: 28 · 2025: 45 · 2024: 17 · 2023: 16
FWCI
2.03
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute of Health Carlos III (PI20/01186, PTQ2019-010412, DIN2020-011302)
  • European Regional Development Fund (Institute of Health Carlos III/ISCIII) (PI20/01186, PTQ2019-010412, DIN2020-011302)
  • Retinitis Pigmentosa Patients of Gipuzkoa Foundation (BEGISARE) (PI20/01186, PTQ2019-010412, DIN2020-011302)
  • Spanish Ministry of Science and Innovation (PI20/01186, PTQ2019-010412, DIN2020-011302)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
subretinal injection, retinal gene therapy, inherited retinal disease, RPE65, voretigene neparvovec, viral vectors, photoreceptors, retinal pigment epithelium

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review